INTRODUCTION {#s1}
============

Colorectal cancer is the third most commonly diagnosed cancer in the world \[[@R1]\]. According to recent reports, the incidence and mortality of colorectal cancer in China have also been increasing in last two decades \[[@R2]\]. It is well known that colorectal cancer susceptibility is related to multiple environmental factors and genetic alterations, such as genetic mutations or polymorphisms \[[@R3], [@R4]\]. Nevertheless, the role of genetic polymorphism and colorectal cancer susceptibility still remains unknown.

Long non-coding RNAs (lncRNAs) are non-coding molecules larger than 200 nucleotides lacking significant protein-coding capacity \[[@R5]\]. It has been reported that lncRNAs are involved in diverse functions in carcinogenesis, including chromatin modification, transcription, and posttranscriptional processing \[[@R6]\]. In addition, previous studies have indicated that polymorphisms in lncRNAs may influence the risk of gastric cancer \[[@R7], [@R8]\]. Recent studies have demonstrated that lncRNA maternally expressed gene 3 (*MEG3*) is abnormal expressed in various human cancers, such as hepatocellular carcinoma \[[@R9], [@R10]\], bladder cancer \[[@R11]\], glioma \[[@R12]\], and gastric cancer \[[@R13]\]. Moreover, *MEG3* overexpression induced cell proliferation and was associated with the development and progression of colorectal cancer \[[@R14]\]. However, little is known about the single nucleotide polymorphisms (SNPs) in *MEG3* and colorectal cancer risk.

On the basis of previous findings mentioned above, as well as the influence of SNPs on *MEG3*, we hypothesis that genetic variants of *MEG3* may modify the development of colorectal cancer. The genetic variants of *MEG3* may be associated with the expression of *MEG3* and consequently influence susceptibility to colorectal cancer. To test the hypothesis, we carried out an association study between tagging SNPs (tagSNPs) in *MEG3* and colorectal cancer risk in a hospital-based colorectal cancer case-control study comprising 518 patients and 527 control subjects from China.

RESULTS {#s2}
=======

The demographic characteristics of participants are described in Table [1](#T1){ref-type="table"}. The average age of the patients was 60.0 years old compared with 59.2 years old in controls, which revealed no statistically difference (*P* = 0.284). Furthermore, there was no significant difference in sex distribution (*P* = 0.972) or smoking status (*P* = 0.292). However, the cases were asked to report a significant high rate of family history of cancer than the controls (*P* \< 0.001). Among 518 patients, the number of cases with colon cancer and rectal cancer were 248 (47.9%) and 270 (52.1%), respectively. The tumor stage for I, II, III, and IV were 38 (7.3%), 214 (41.3%), 179 (34.6%), and 87 (16.8%), respectively.

###### Distribution of characteristics among cases and controls

  Variable                                              Cases (*n* = 518)   Controls (*n* = 527)   *P*
  ----------------------------------------------------- ------------------- ---------------------- ----------
  Age (mean ± SD)[^a^](#tfn_001){ref-type="table-fn"}   60.0 ± 12.4         59.2 ± 9.4             0.284
  Gender                                                                                           
   Male                                                 320 (61.8)          325 (61.7)             0.972
   Female                                               198 (38.2)          202 (38.3)             
  Smoking status                                                                                   
   Non-smokers                                          347 (67.0)          369 (70.0)             0.292
   Smokers                                              171 (33.0)          158 (30.0)             
  Family history of cancer                                                                         
   No                                                   405 (78.2)          488 (92.6)             \< 0.001
   Yes                                                  113 (21.8)          39 (7.4)               
  Site                                                                                             
   Colon                                                248 (47.9)                                 
   Rectum                                               270 (52.1)                                 
  Stage                                                                                            
   I                                                    38 (7.3)                                   
   II                                                   214 (41.3)                                 
   III                                                  179 (34.6)                                 
   IV                                                   87 (16.8)                                  

SD, standard deviation

The primary information of six SNPs in *MEG3* is summarized in Table [2](#T2){ref-type="table"}. All SNPs in both cases and controls showed a call rate \> 97.0%. The genotype frequencies in controls were in line with the Hardy-Weinberg equilibrium model (*P* = 0.712 for rs3087918, *P* = 0.930 for rs11160608, *P* = 0.812 for rs7158663, *P* = 0.521 for rs4081134, and *P* = 0.221 for rs10144253).

###### Association analyses between SNPs in *MEG3* and colorectal cancer risk

  SNP          Position    MAF in casea   MAF in control[^a^](#tfn_002){ref-type="table-fn"}   Call rate   HWE in case   HWE in control   OR (95%CI)[^b^](#tfn_003){ref-type="table-fn"}   *P*[^b^](#tfn_003){ref-type="table-fn"}
  ------------ ----------- -------------- ---------------------------------------------------- ----------- ------------- ---------------- ------------------------------------------------ -----------------------------------------
  rs3087918    101297963   0.367          0.381                                                100.0%      0.344         0.712            0.94 (0.79-1.12)                                 0.493
  rs11160608   101313093   0.433          0.436                                                100.0%      1.000         0.930            0.98 (0.82-1.16)                                 0.788
  rs7158663    101319424   0.295          0.242                                                98.9%       0.138         0.812            1.31 (1.08-1.59)                                 0.007
  rs4081134    101321788   0.227          0.219                                                97.8%       0.314         0.521            1.04 (0.84-1.29)                                 0.711
  rs10144253   101325962   0.470          0.472                                                99.8%       0.659         0.221            0.98 (0.82-1.17)                                 0.843

Minor allele frequency.

Additive model adjusted for age, sex, and smoking status.

As shown in Table [2](#T2){ref-type="table"}, the allele frequency of rs7158663 exhibited a significant difference between case and control groups (*P* = 0.007). The minor allele frequency (MAF) of rs7158663 in cases and controls were 0.295 and 0.242, respectively. However, no significant association with colorectal cancer was identified for other five SNPs (*P* = 0.493 for rs3087918, *P* = 0.788 for rs11160608, *P* = 0.711 for rs4081134, and *P* = 0.843 for rs10144253). In addition, after adjusting for multiple testing using Bonferroni correction, rs7158663 was still significant (*P* = 0.035).

We further performed a multivariate logistic regression analysis for rs7158663 by adjusting age, sex, and smoking. As listed in Table [3](#T3){ref-type="table"}, rs7158663 AA genotype, but not GA genotype, had a significantly elevated risk of colorectal cancer, compared with GG genotype (*P* = 0.007) (OR = 1.96 and *P* = 0.006 for AA versus GG, and OR = 1.20 and *P* = 0.171 for GA versus GG). For genetic models, rs7158663 was significant between cases and controls in dominant, recessive, and additive models (*P* = 0.035, 0.012, and 0.007, respectively).

###### Genotype frequencies of *MEG3* rs7158663 among cases and controls and their association with colorectal cancer risk

  Genotype    Cases (*n* = 516)   Controls (*n* = 517)   OR (95%CI)a        *P*[^a^](#tfn_004){ref-type="table-fn"}
  ----------- ------------------- ---------------------- ------------------ -----------------------------------------
  GG          264 (51.2)          298 (57.6)             1.00               
  GA          200 (38.7)          188 (36.4)             1.20 (0.92-1.56)   0.171
  AA          52 (10.1)           31 (6.0)               1.96 (1.22-3.17)   0.006
  Dominant                                               1.31 (1.02-1.67)   0.035
  Recessive                                              1.82 (1.14-2.91)   0.012
  Additive                                               1.31 (1.08-1.59)   0.007

Adjusted for age, sex, and smoking status.

We next evaluated the stratified association of rs7158663 with colorectal cancer risk by age, sex, family history of cancer, and smoking habits (Table [4](#T4){ref-type="table"}). We observed that the GA/AA genotype hadan increased risk of colorectal cancer (OR = 1.31, *P* = 0.035). This increased effect was also more evident in subgroups of age ≤ 60 (OR = 1.71, *P* = 0.003) and patients with family history (OR = 1.25, *P* = 0.011). Nevertheless, no significant evidence was found for interaction between rs7158663 and these two factors.

###### Stratified analyses for *MEG3* rs7158663 genotypes in cases and controls

  Variable                   GG        GA/AA     OR (95%CI)[^a^](#tfn_005){ref-type="table-fn"}   *P*[^a^](#tfn_005){ref-type="table-fn"}
  -------------------------- --------- --------- ------------------------------------------------ -----------------------------------------
  Age (y), median                                                                                 
   ≤60                       104/158   124/111   1.71 (1.20-2.44)                                 0.003
   \>60                      160/140   128/108   1.04 (0.74-1.46)                                 0.844
  Gender                                                                                          
   Male                      167/177   152/142   1.15 (0.84-1.57)                                 0.396
   Female                    97/121    100/77    1.62 (0.98-2.34)                                 0.076
  Smoking status                                                                                  
   Non-smokers               168/207   178/155   1.42 (0.96-1.87)                                 0.062
   Smokers                   96/91     74/64     1.10 (0.70-1.71)                                 0.679
  Family history of cancer                                                                        
   No                        204/268   200/210   1.25 (0.96-1.63)                                 0.099
   Yes                       60/30     52/9      2.98 (1.28-6.92)                                 0.011

Adjusted for age, sex, and smoking status.

We evaluated the correlations between rs7158663 and clinical features of colorectal cancer, including tumor site and stage. As shown in Table [5](#T5){ref-type="table"}, no significant relationship was observed (*P* = 0.842 for tumor site, and *P* = 0.601 for tumor stage).

We peformed an *in silico* analysis of rs7158663 on *MEG3* by RNAsnp. As shown in Figure [1](#F1){ref-type="fig"}, the RNAsnp predicted that rs7158663 G-A allele substitution leaded to a minimum free energy (MFE) change from −53.30 kcal/mol to −55.20 kcal/mol. Moreover, the base pair probabilities were different between rs7158663 G allele and A allele.

###### Association analyses between *MEG3* rs7158663 genotypes and clinicalpathologic characteristics of cases

  Variable   GG           GA/AA        OR (95%CI)[^a^](#tfn_006){ref-type="table-fn"}   *P*[^a^](#tfn_006){ref-type="table-fn"}
  ---------- ------------ ------------ ------------------------------------------------ -----------------------------------------
  Site                                                                                  
   Colon     126 (24.4)   122 (23.6)   1.00                                             
   Rectum    138 (26.7)   130 (25.2)   1.04 (0.73-1.46)                                 0.842
  Stage                                                                                 
   I/II      126 (24.4)   125 (24.2)   1.00                                             
   III/IV    138 (26.7)   127 (24.6)   1.10 (0.78-1.55)                                 0.601

Adjusted for age, sex, and smoking status.

![The predicting rs7158663 on *MEG3* secondary structure\
**a.** UCSC genome browser view for structure-disruptive rs7158663. **b.** Minimum free energy structures of rs7158663. **c.** Dot plot of the global structure.](oncotarget-07-19054-g001){#F1}

DISCUSSION {#s3}
==========

We investigated the association of tagSNPs of *MEG3* with colorectal cancer risk in a population of Chinese. We demonstrated, for the first time, that rs7158663 in *MEG3* had a strong association with increased risk of colorectal cancer. In addition, the elevated risk was greater for subjects with age ≤ 60 and family history of cancer. These results suggested that rs7158663 may be a susceptibility SNP for colorectal cancer in Chinese populations.

Given *MEG3* is a lncRNA that plays critical roles in tumor cellular proliferation, migration and invasion \[[@R13], [@R15], [@R16]\], SNPs in *MEG3* may affect cell phenotypes and cause the risk of developing cancer. *MEG*3 is located on chromosome 14q32, a region proposed to contain putative tumor suppressors \[[@R17]\]. Although the regulation of *MEG3* and its precise mechanism of action in cancer are still well known, emerging evidence strongly demonstrates that *MEG3* functions as a novel lncRNA tumor suppressor \[[@R18]\]. In additional to colorectal normal tissue, *MEG3* is highly expressed in brain, lung, and liver \[[@R19]\]. Interestingly, we found that *MEG3* rs7158663 is correlated to significantly increased risk of colorectal cancer, which may be explained by the finds from Yin et al. \[[@R14]\]. They found that *MEG3* predicts a poor prognosis of colorectal cancer by influencing cell proliferation.

Until now, some studies have indicated that SNPs in lncRNAs could potentially impact various biological processes by influencing biological pathways. For example, Yang et al. first revealed the relationship between lncRNA *H19* and gastric cancer; they found an important role for *H19* variants in gastric cancer carcinogenesis \[[@R8]\]. Zhang et al. identified an allelic regulation of rs920778 on lncRNA *HOTAIR* expression, as well as associated with the development and progression of esophageal squamous cell carcinoma \[[@R20]\]. The novel function of rs920778 on *HOTAIR* was further confirmed in other cancer, including colorectal cancer \[[@R21]\], gastric cancer \[[@R22]\], and breast cancer \[[@R23]\]. The RNAsnp prediction revealed that rs7158663 in *MEG3* changed the folding structures of *MEG3*. Therefore, we speculate that rs7158663 could be a regulatory SNP, which regulate expression of *MEG3* and contribute to genetic susceptibility of colorectal cancer.

Several limitations of the present study should be mentioned. Firstly, these findings were based on genetic analysis of a single gene with a relatively small size of colorectal cancer patients, which need to be validated using an independent prospective clinical study. Secondly, our study was based on a hospital-based study; therefore, potentially important sources of selection bias may exist. Thirdly, diet is a major determinant of risk for colorectal cancer \[[@R24]\]; however, our study had incomplete information on dietary consumption. Further studies are needed to determine the association between dietary information and genetic variants in *MEG3*.

In summary, we identified a genetic susceptibility SNP rs7158663 for colorectal cancer in Chinese. The SNP rs7158663 in *MEG3* played a vital role in colorectal carcinogenesis. These data suggest that genetic variants in *MEG3* may serve as potential risk factor and targets for colorectal cancer therapy in the further.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

This study consisted of 518 colorectal cancer cases and 527 control subjects from the hospitals of Southeast University Medical College. All cases were patients newly diagnosed with histologically confirmed colorectal adenocarcinomas who were admitted to the hospitals. No patient had received radiotherapy or chemotherapy. Controls were frequency-matched with cases on age and sex who were recruited at the same time period. All controls were unrelated ethnic Han Chinese and these subjects had no history of cancer. All participants provided informed consent after the interview. This research protocol was approved by the Institutional Review Board of Southeast University Medical College.

SNPs selection {#s4_2}
--------------

We selected the tagSNPs of *MEG3* with the MAF \> 0.05 in Han Chinese from the 1000 Genome Projects. As a result, six tagSNPs were selected using a pairwise Tagger method with *r*^2^ \> 0.8 to capture other SNPs, rs10144253.

Genotyping {#s4_3}
----------

Genomic DNA was extracted from peripheral blood using the TIANamp Blood DNA kit (Tiangen, China). Genotyping was performed by TaqMan SNP genotyping assay. Real-time TaqMan PCR and genotyping were conducted on an ABI 7500 real-time PCR System (Applied Biosystems, USA). The results of allelic discrimination were analyzed using SDS 2.4 software. For quality control, we included two negative controls (water) and two duplicates in each 96-well plate. Furthermore, about 3% of selected samples were repeated genotyping to confirm the results in a blind fashion.

Statistical analysis {#s4_4}
--------------------

Tests for the Hardy-Weinberg equilibrium in cases and controls were performed by good-of-fit χ^2^ test. Student\'s t-test or χ^2^ test was used to assess the significance of any differences in frequency distributions of demographic variables and genotypes among cases and controls. We estimated the association between genotypes and colorectal cancer risk by odds ratios (ORs) and 95% confidence intervals (CIs) using the logistic regression. The ORs and 95%CIs were further adjusted by for age, sex, and smoking habits. All analyses were two-sided and *P* \< 0.05 was considered significant. All statistical calculations were conducted with SPSS 13.0 software (SPSS Inc., Chicago, IL, USA).
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